ASX-listed biotech Prescient Therapeutics is crossing a major inflection point on the back of three milestone announcements made within a span of less than eight weeks – including one today.

The company this morning announced a strategic collaboration with MD Anderson Cancer Center, the largest cancer centre in the US, with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat haematological malignancies.

The agreement is designed to combine Prescient’s OmniCAR platform with a proprietary binder discovered by MD Anderson’s ECLIPSE platform.

“We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for blood cancers,” Prescient CEO and MD Steven Yatomi-Clarke said.

“Adding this TCR-like binder to Prescient’s armament changes the game by now being able to also target aberrant proteins inside the cancer cell that have been brought to the cell surface.”

Mr Yatomi-Clarke said this represented the “first important steps in creating a cell therapy ecosystem with OmniCAR at its heart, being adapted to match the antigen profile of individual patients”.

This follows a recent agreement struck with cell manufacturer Q-Gen, plus the ongoing clinical trial progress to its targeted therapies PTX-100 and PTX-200 (both of which have now received FDA Orphan Drug Designation status).

A two-year journey of shareholder value creation, laden with milestones

Recapping from their capital raise just over two years ago at a share price of 5.5 cents, Prescient has substantially progressed all their programs and grown their whole portfolio, which has driven strong shareholder value. They achieved this using less than half of the $20.3 million they had on hand in August 2020. Their share price and market cap have since multiplied on the back of a series of milestone events, as the below graph illustrates. They continue to build upon this work seeking to drive Prescient to new levels.

Strong run for PTX-100 and PTX-200

Prescient’s targeted therapies PTX-100 and PTX-200 have showcased their potential with highly encouraging results. Both programs advanced steadily through clinical trials exhibiting excellent safety profiles.

By the end of 2022, the company aims to focus on and complete an expansion cohort for PTX-100 in a study of T-cell lymphomas. Furthermore, the US FDA has recently granted PTX-100 Orphan Drug Designation status which confers several developmental benefits and seven years of market exclusivity upon approval.

Beyond expectations – OmniCAR and CellPryme-M

When Prescient started out with OmniCAR, they had secured the platform but had not yet articulated a development plan for it, and were still in the early days of assembling a specialist team to drive it forward.

Since then, the company conducted a strategic review, built a world class advisory board and internal team, identified three internal CAR-T programs and proceeded to develop these with urgency.

OmniCAR has demonstrated overwhelmingly encouraging results to date and a key US patent in July 2022 protects the platform in the world’s largest healthcare market out to at least 2039. 

On the back of these developments, they recently unveiled the clinic-ready CellPryme-M cell therapy enhancement platform, opening up entirely new commercial avenues for external collaborations.

World-class pedigree of partnerships and collaborations

When Prescient started out with OmniCAR, they had secured the platform but had not yet articulated a development plan for it, and were still in the early days of assembling a specialist team to drive it forward.

Since then, the company conducted a strategic review, built a world class advisory board and internal team, identified three internal CAR-T programs and proceeded to develop these with urgency.

OmniCAR has demonstrated overwhelmingly encouraging results to date and a key US patent in July 2022 protects the platform in the world’s largest healthcare market out to at least 2039. 

On the back of these developments, they recently unveiled the clinic-ready CellPryme-M cell therapy enhancement platform, opening up entirely new commercial avenues for external collaborations.

Join Prescient Therapeutics MD and CEO Steven Yatomi-Clarke for an online investor briefing on Thursday 8th September at 7pm (AEST). Steven will discuss how Prescient are changing the cancer conversation from ‘treatment’ to ‘cure’ and also provide an update on recent announcements. Click here to register.

Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.

Sources:

• Prescient Therapeutics ASX Announcement, Key OmniCAR US Patent Granted 
• Prescient Therapeutics ASX Announcement, US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
• Prescient Therapeutics ASX Announcement, Prescient Unveils Clinic-Ready CellPryme-M Platform for Enhancing Cell Therapies
• Prescient Therapeutics ASX Announcement, Prescient Scientific Advisory Board Enhanced by Two International CAR-T and Bioengineering Experts
• Prescient Therapeutics ASX Announcement, Internationally Renowned Brain Cancer Expert Professor Donald M. O’Rourke, MD of Penn Joins Prescient Scientific Advisory Board
• Prescient Therapeutics ASX Announcement, Prescient Appoints Leading Cancer Researcher, Prof Phillip Darcy of Peter MacCallum Cancer Centre, to Scientific Advisory Board
• Prescient Therapeutics ASX Announcement, Prescient achieves key milestone by demonstrating OmniCAR’s key components show minimal immunogenicity in silico
• Prescient Therapeutics ASX Announcement, Recruitment Open for Expansion Cohort of Phase 1B Study of PTX-100 in Patients with T Cell Lymphomas 
• Prescient Therapeutics ASX Announcement, Prescient signs Manufacturing Agreement for Next Generation CAR-T Therapy